Document is current

Article History

Received: 5 June 2024

Accepted: 5 June 2024

First Online: 24 June 2024

Disclosure

: MBP has received fees for professional services from Servier, Roche, Bristol-Myers Squibb, Astra Zenica, Elekta. AMH has received fees for professional service from Telix. RAS has received fees for professional services from SkylineDx BV, IO Biotech ApS, MetaOptima Technology Inc., F. Hoffmann-La Roche Ltd, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc., Bristol-Myers Squibb, Myriad Genetics, GlaxoSmithKline. CAB leads clinical trials supported by Elekta, Merck, Amgen, EMD Serono, Alpha Tau Medical and Regeneron for which his institution has received funding. He has served as a paid scientific advisor to Regeneron and an unpaid scientific advisor to Castle Biosciences. His institution received funding from the trial sponsor to support conduct of this clinical trial. He acknowledges the United States National Cancer Institute for providing a Cancer Center Support Grant (P30 VA008748) to Memorial Sloan Kettering Cancer Center (PI: Selwyn Vickers, MD). The origin of this funding was from "Cancer Australia." Institution also received support from the United States National Cancer Institute Cancer Center Support Grant to Memorial Sloan Kettering Cancer Center (P30 CA008748). MCF has received fees for professional services from Elekta and Varian. All other authors have no competing interests to declare.